Genmab Reports Thursday With Analysts Watching Whether Margin Collapse Was Temporary

Genmab A/S ADR (GMAB) reports Q2 2026 earnings before market open on August 6, 2026, with analysts expecting $0.37 per share—a sharp 31.48% decline from the $0.54 reported in the same quarter last year. The central question: can the Danish biotech stabilize earnings after a volatile year that saw a dramatic Q4 2025 miss followed by mixed recovery, or will the year-over-year decline signal deeper challenges in its antibody therapy franchise?

Part 1: Earnings Preview

Genmab is a Danish biopharmaceutical company specializing in the development and commercialization of antibody therapeutics for cancer treatment, with key products including Darzalex (daratumumab) and Tepezza (teprotumumab). The company generates revenue through product sales and royalties from partnerships with major pharmaceutical companies.

Genmab reports Q2 2026 earnings before market open on August 6, 2026. Analysts expect $0.37 per share on four estimates ranging from $0.30 to $0.42. The most recent quarter (Q1 2026) delivered $0.15 per share, meeting the $0.15 consensus exactly after a disastrous Q4 2025 that missed by 89%. Compared to Q2 2025's $0.54 per share, the current estimate implies a 31.48% year-over-year decline—a significant headwind that raises questions about the sustainability of the company's growth trajectory.

Three key themes define this earnings story:

Revenue Trajectory and Partnership Performance: Analysts are closely watching whether Genmab can stabilize revenue after recent volatility. Consensus estimates call for $5.81 billion in quarterly revenue, though recent quarters have shown significant misses against elevated expectations. The performance of key partnerships—particularly Darzalex royalties and Tepezza sales—will be critical to meeting the lowered bar.

Margin Pressure and Profitability Concerns: The sharp year-over-year EPS decline despite ongoing product sales suggests margin compression or increased operating expenses. Investors will scrutinize whether the Q4 2025 collapse was a one-time event or signals structural profitability challenges as the company scales its commercial operations.

Pipeline Progress and Future Growth Drivers: With current-year EPS estimates down 28.57% but next-year estimates projecting a 42.73% rebound to $1.57, the market is looking for evidence that Genmab's clinical pipeline can drive a return to growth. Updates on late-stage trials and regulatory progress will be essential to validating the recovery narrative.

Analyst commentary ahead of the release reflects cautious optimism tempered by recent execution concerns. The consensus has been revised downward significantly from earlier expectations, with the Street now modeling a more conservative outlook until the company demonstrates consistent operational performance.

Part 2: Historical Earnings Performance

Genmab's recent earnings history reveals extreme volatility and inconsistent execution. Over the past four quarters, the company has delivered two strong beats, one exact match, and one catastrophic miss—a pattern that suggests operational unpredictability rather than steady performance.

The most striking feature is the Q4 2025 disaster, where GMAB reported $0.05 against a $0.46 estimate—an 89.13% miss that represents one of the most severe quarterly disappointments in the company's recent history. This followed two consecutive solid beats: Q2 2025's $0.54 (38.46% beat) and Q3 2025's $0.65 (35.42% beat). The Q1 2026 result of $0.15 exactly matched estimates, suggesting the company may have stabilized but has yet to demonstrate a return to the upside surprise pattern.

The trend is concerning: after delivering consistent beats in mid-2025, the company stumbled badly in Q4 and has since only managed to meet—not exceed—expectations. This shift from outperformance to meeting or missing estimates suggests either deteriorating fundamentals or that analysts have not yet fully adjusted their models to reflect the company's new operating reality. The upcoming Q2 report will be critical in determining whether Q4 was an anomaly or the beginning of a more challenging period.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Genmab reports before market open, meaning Day 0 captures the first full trading session reaction to results, while Day +1 reflects follow-through momentum.

Historical price behavior shows moderate volatility with no clear directional bias. The average absolute Day 0 move is 2.98% with a range of 4.54%, while Day +1 averages 2.96% with a 2.77% range.

Recent earnings have produced mixed reactions: the most recent Q1 2026 report triggered a 2.98% decline on Day 0 despite meeting estimates, while the Q4 2025 miss generated almost no immediate reaction (just 0.10% down) but followed with a 2.80% decline the next day. The Q3 2025 beat saw minimal Day 0 movement (1.20% down) but also limited follow-through. Notably, the Q2 2025 strong beat produced a 5.49% Day 0 gain that completely reversed to a 5.55% Day 1 loss—suggesting profit-taking overwhelmed the positive surprise.

The pattern suggests muted initial reactions that can extend or reverse on Day +1, with no reliable correlation between earnings surprises and sustained price direction. Investors should expect mid-single-digit percentage moves in either direction, with the potential for Day 1 reversals regardless of the initial reaction.

Part 2.2: Options Market Expected Move

The options market is pricing a 10.46% expected move through the August 21 expiration—significantly larger than the historical average Day 0 move of 2.98% and even exceeding the typical Day 0 range of 4.54%. This elevated implied volatility of 80.34% suggests options traders are anticipating a more dramatic reaction than recent history would indicate, possibly reflecting heightened uncertainty around the company's ability to stabilize after the Q4 2025 collapse.

Part 3: What Analysts Are Saying

Analysts maintain a strongly bullish stance on Genmab despite recent execution challenges. The consensus rating stands at 4.47 out of 5.0 (between Buy and Strong Buy), with 15 Strong Buy ratings, 0 Moderate Buys, 3 Holds, 0 Moderate Sells, and 1 Strong Sell among 19 analysts covering the stock. This represents an improved sentiment from one month ago when the rating was 4.40, as one analyst upgraded from Hold to a more bullish stance.

The average price target of $37.96 implies 29.8% upside from the current price of $29.26, with estimates ranging from a low of $32.00 (9.4% upside) to a high of $43.00 (47.0% upside). The tight clustering of targets around the mean suggests broad agreement on valuation, while the overwhelmingly bullish rating distribution indicates analysts view current weakness as a buying opportunity rather than a fundamental deterioration.

The recent sentiment improvement is notable given the company's volatile earnings performance—it suggests analysts believe the Q4 2025 miss was an aberration and that the underlying business fundamentals remain intact. The 79% Strong Buy rating (15 of 19 analysts) is particularly striking and reflects confidence that Genmab's pipeline and partnership portfolio will drive a return to growth despite near-term earnings pressure.

Part 4: Technical Picture

Genmab enters earnings with strengthening technical momentum after a recent shift in sentiment. The Barchart Technical Opinion has improved dramatically from 24% Sell one month ago and 24% Sell one week ago to 40% Buy currently—a significant reversal that suggests growing bullish conviction heading into the report.

Timeframe Analysis:

• Short-term (50% Buy): Moderate buy signal indicates near-term momentum has turned positive after recent weakness
• Medium-term (Hold): Neutral reading suggests the intermediate trend remains in consolidation mode
• Long-term (50% Buy): Moderate buy signal reflects improving sentiment in the longer-term trend structure

Trend Characteristics: The trend is characterized as Weak strength with Average direction, suggesting momentum is building but lacks conviction—a setup that could amplify volatility around the earnings release.

The stock is trading at $29.26, positioned above all major moving averages: the 5-day ($28.89), 10-day ($28.88), 20-day ($28.85), 50-day ($27.16), 100-day ($27.06), and 200-day ($29.00). This clean technical setup with the stock above its entire moving average stack is constructive, though the proximity to the 200-day average (just $0.26 above) means a disappointing report could quickly trigger a breakdown below long-term support.

The 50-day moving average at $27.16 represents the first major support level, while the 200-day at $29.00 serves as immediate support just below current levels. The recent breakout above all moving averages combined with improving short-term and long-term signals creates a supportive technical setup for earnings, but the weak trend strength and elevated options-implied volatility suggest the market is bracing for a significant move. A beat could trigger momentum continuation toward the $32 analyst low target, while a miss risks a swift retreat to the 50-day support zone.